CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION- carbinoxamine maleate suspension, extended release

Carbinoxamine Maleate Extended-Release Oral Suspension by

Drug Labeling and Warnings

Carbinoxamine Maleate Extended-Release Oral Suspension by is a Prescription medication manufactured, distributed, or labeled by Neos Therapeutics LP, Tris Pharma, Inc. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    Carbinoxamine Maleate extended-release oral suspension is indicated for adults and pediatric patients 2 years of age and older for the symptomatic treatment of:

    • Seasonal and perennial allergic rhinitis
    • Vasomotor rhinitis
    • Allergic conjunctivitis due to inhalant allergens and foods
    • Mild, uncomplicated allergic skin manifestations of urticaria and angioedema
    • Dermatographism
    • As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled
    • Amelioration of the severity of allergic reactions to blood or plasma
  • 2 DOSAGE AND ADMINISTRATION

    2.1 Overview

    The dosage of Carbinoxamine Maleate Extended-Release Oral Suspension should be individualized based on the severity of the condition and the response of the patient. Start with lower doses and increase as needed and tolerated.

    2.2 Administration

    Administer Carbinoxamine Maleate Extended-Release Oral Suspension by the oral route only. Measure Carbinoxamine Maleate Extended-Release Oral Suspension with an accurate milliliter measuring device. A household teaspoon is not an accurate measuring device and could lead to overdosage. A pharmacist can provide an appropriate measuring device and can provide instructions for measuring the correct dose.

    2.3 Recommended Dosage for Adults and Adolescents 12 years of age and older:

    7.5 mL to 20 mL (6 mg to 16 mg) every 12 hours administered orally

    2.4 Recommended Dosage for Pediatric Patients 2 to 11 years of age (approximately 0.2 to 0.4 mg/kg/day):

    2 to 3 years: 3.75 mL to 5 mL (3 mg to 4 mg) every 12 hours administered orally
    4 to 5 years: 3.75 mL to 10 mL (3 mg to 8 mg) every 12 hours administered orally
    6 to 11 years: 7.5 mL to 15 mL (6 mg to 12 mg) every 12 hours administered orally

  • 3 DOSAGE FORMS AND STRENGTHS

    Extended-release oral suspension: 4 mg carbinoxamine maleate per 5 mL

  • 4 CONTRAINDICATIONS

    Carbinoxamine Maleate Extended-Release Oral Suspension is contraindicated in:

    • children younger than 2 years of age because deaths have been reported in this age group [see Warnings and Precautions (5.1)].
    • patients who are hypersensitive to carbinoxamine maleate or any of the inactive ingredients in Carbinoxamine Maleate Extended-Release Oral Suspension [see Warnings and Precautions (5.4)].
    • patients who are taking monoamine oxidase inhibitors (MAOI) [see Drug Interactions (7)].
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Pediatric Mortality

    Deaths have been reported in children less than 2 years of age who were taking carbinoxamine-containing drug products; therefore, Carbinoxamine Maleate Extended-Release Oral Suspension is contraindicated in children younger than 2 years of age.

    5.2 Somnolence and Impaired Mental Alertness

    Carbinoxamine Maleate Extended-Release Oral Suspension may produce marked drowsiness and impair the mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Advise patients to avoid engaging in hazardous tasks requiring mental alertness and motor coordination after ingestion of Carbinoxamine Maleate Extended-Release Oral Suspension. Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur.

    5.3 Concomitant Medical Conditions

    Carbinoxamine Maleate Extended-Release Oral Suspension has anticholinergic (atropine-like) properties and, therefore, should be used with caution in patients with: increased intraocular pressure, narrow angle glaucoma, hyperthyroidism, cardiovascular disease, hypertension, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck obstruction, or pyloroduodenal obstruction.

    5.4 Allergic Reactions due to Sulfites, including Anaphylaxis

    Carbinoxamine Maleate Extended-Release Oral Suspension contains sodium metabisulfite, a sulfite that may cause allergictype
    reactions, including anaphylaxis and life-threatening or less severe asthmatic episodes, in susceptible individuals. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic individuals.

  • 6 ADVERSE REACTIONS

    The following clinically significant adverse reactions are described elsewhere in the labeling:

    • Somnolence and Impaired Mental Alertness [see Warnings and Precautions (5.2)]
    • Allergic Reactions due to Sulfites, including Anaphylaxis [see Warnings and Precautions (5.4)]

    The most frequent adverse reactions include: sedation, sleepiness, dizziness, disturbed coordination, epigastic distress, and thickening of bronchial secretions. In clinical use, younger children and older adults may be particularly sensitive to adverse reactions [see Pediatric Use (8.4) and Geriatric Use (8.5)].


    The following adverse reactions, listed by body system, have been identified in case reports and during the use of carbinoxamine in observational studies. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Body as a Whole: Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and throat.

    Cardiovascular: Hypotension, headache, palpitations, tachycardia, extrasystoles.

    Central Nervous System: Fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions.

    Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, constipation.
    Hematologic: Hemolytic anemia, thrombocytopenia, agranulocytosis.

    Laboratory: Increase in uric acid levels.
    Respiratory: Tightness of chest and wheezing, nasal stuffiness.

    Urogenital: Urinary frequency, difficult urination, urinary retention, early menses.

  • 7 DRUG INTERACTIONS

    • Do not use Carbinoxamine Maleate extended-release oral suspension in patients who are taking monoamine oxidase inhibitors (MAOIs), which prolong and intensify the anticholinergic (drying) effects of antihistamines.
    • Avoid use of Carbinoxamine Maleate extended-release oral suspension with alcohol and other CNS depressants

    (hypnotics sedatives, tranquilizers, etc.) due to additive effects.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary
    Published data over decades of use of antihistamines, including carbinoxamine, have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. However, published data specifically evaluating the risk of carbinoxamine were not found. Animal reproductive studies have not been conducted with carbinoxamine maleate.


    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

    8.2 Lactation

    Risk Summary
    Based on the physical properties of carbinoxamine, it is likely that carbinoxamine is present in breastmilk. There are published reports of drowsiness and irritability in infants exposed to antihistamines via breast milk. There are postmarketing reports of deaths in children under 2 years of age exposed to carbinoxamine by oral administration. There are no available data on the effects on milk production. It
    is not recommended to breastfeed during treatment with Carbinoxamine Maleate extended-release oral suspension [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4)].

    8.4 Pediatric Use

    Carbinoxamine Maleate extended-release oral suspension is contraindicated in pediatric patients younger than 2 years of age because deaths have been reported in this patient population who were taking carbinoxamine-containing drug products [see Contraindications (4) and Warnings and Precautions (5.1)].


    The safety and effectiveness of Carbinoxamine Maleate extended-release oral suspension in pediatric patients aged 2 years and older have been established and is based on demonstration of bioequivalence to the immediate-release reference product [see Clinical Pharmacology (12.3)]. Carbinoxamine may diminish mental alertness or produce sedation in children. Paradoxical reactions with excitation are more likely in younger children.

    8.5 Geriatric Use

    Carbinoxamine Maleate extended-release oral suspension may cause dizziness, hypotension, confusion, or over-sedation in the elderly. Start elderly patients on lower doses and observed closely.

  • 10 OVERDOSAGE

    Overdosage with carbinoxamine may cause central nervous system depression or stimulation, hallucinations, convulsions, and death. Atropine-like signs and symptoms – dry mouth; fixed, dilated pupils; flushing; and gastrointestinal symptoms may also occur.

    The treatment of overdosage consists of discontinuation of Carbinoxamine Maleate extended-release oral suspension and institution of symptomatic and supportive therapy. Vital signs (including respiration, pulse, blood pressure, and temperature) and EKG should be monitored.


    Induction of vomiting is not recommended. Activated charcoal should be given and gastric lavage should be considered after ingestion of a potentially life-threatening amount of drug. In the presence of severe anticholinergic effects, physostigmine may be useful. Vasopressors may be used to treat hypotension.

  • 11 DESCRIPTION

    Each 5 mL of Carbinoxamine Maleate extended-release oral suspension contains carbinoxamine complexed with polistirex equivalent to 4 mg carbinoxamine maleate and the following inactive ingredients: citric acid anhydrous, strawberry-banana flavor, glycerin, high fructose corn syrup, methylparaben, modified food starch, polysorbate 80, polyvinyl acetate, povidone, propylparaben, purified water, sodium metabisulfite, sodium polystyrene sulfonate, sucrose, triacetin, and xanthan gum.

    Carbinoxamine maleate is freely soluble in water. The chemical name is 2-[(4-chlorophenyl)-2- pyridinylmethoxy]-N, N-dimethylethanamine (Z)-2-butenedioate (1:1), which has the following structure:

    structure 1

    C16H19ClN2O·C4H4O4 MW = 406.86

    The drug-polistirex complex is formed with the active ingredient (carbinoxamine maleate, USP) and sodium polystyrene sulfonate, USP, which has the following structure:

    Structure 2

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Carbinoxamine is an H1 receptor antagonist (antihistamine) that exhibits anticholinergic (drying) and sedative properties.

    Antihistamines compete with histamine for receptor sites on effector cells.

    12.3 Pharmacokinetics

    Carbinoxamine Maleate extended-release oral suspension after single-dose administration of 16 mg was bioequivalent to the reference carbinoxamine immediate-release oral solution after the administration of two doses of 8 mg six hours apart under fasting conditions. The carbinoxamine mean (SD) peak plasma concentration (Cmax) was 28.7 (5.3) ng/mL at 6.7 hours after Carbinoxamine Maleate extended-release oral suspension administration. The plasma half-life of carbinoxamine was 17.0 hours. There was no effect of food on the pharmacokinetic parameters.

    Carbinoxamine Maleate extended-release oral suspension after multiple-dose administration of 16 mg every 12 hours for 8 days was bioequivalent to the reference carbinoxamine immediate-release oral solution after multiple-dose administration of 8 mg every 6 hours. The mean (SD) steady-state Cmax was 72.9 (24.4) ng/mL at 5.6 hours after Carbinoxamine Maleate extended-release oral suspension
    administration. Carbinoxamine mean (SD) minimum plasma concentration at steady-state was 51.8 (20.3) ng/mL.

  • 13 NONCLINCAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    No long-term studies in animals have been performed to determine the possible effects of carbinoxamine on carcinogenesis, mutagenesis, and fertility.

  • 14 CLINICAL STUDIES

    The effectiveness and safety of Carbinoxamine Maleate extended-release oral suspension is based on demonstration of bioequivalence to the immediate-release reference product [see Pharmacokinetics (12.3)].

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Carbinoxamine Maleate extended-release oral suspension contains 4 mg carbinoxamine maleate per 5 mL. It is a light beige to tan viscous suspension with strawberry banana flavor and is supplied as follows:

    NDC: 62542-101-05 Bottles of 16 fl oz (480 mL)

    Store at 25ºC (77ºF); excursions permitted from 15ºC to 30ºC (59ºF to 86ºF). [See USP Controlled Room Temperature].

    Dispense in tight, light-resistant container with child-resistant closure.

  • 88436-1 - Section Title Not Found In Database

    Administration
    Advise patients to measure Carbinoxamine Maleate extended-release oral suspension with an accurate milliliter measuring
    device. A household teaspoon is not an accurate measuring device and could lead to overdosage [see Dosage and Administration (2.2)].

    Activities Requiring Mental Alertness
    Advise patients to use caution when driving a motor vehicle or operating machinery. Carbinoxamine Maleate extended-release
    oral suspension may produce marked drowsiness and impair the mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery [see Warnings and Precautions (5.2)].

    Alcohol, Sedatives, and Tranquilizers
    Advise patients to avoid the use of alcoholic beverages, sedatives, and tranquilizers while taking Carbinoxamine Maleate extended-release oral suspension because additional reduction in mental alertness may occur [see Warnings and Precautions (5.2) and Drug Interactions (7)].


    MAOIs
    Advise patients to not use MAOIs while taking Carbinoxamine Maleate extended-release oral suspension. MAOIs may prolong and intensify the anticholinergic (drying) effects [see Contraindications (4) and Drug Interactions (7)].

    Lactation
    Advise women that breastfeeding is not recommended during treatment with Carbinoxamine Maleate extended-release oral suspension [see Warnings and Precautions (5.1) and Use in Specific Populations (8.2)].


    Manufactured by:
    Tris Pharma, Inc.
    Monmouth Junction, NJ 08852
    www.trispharma.com

    For:

    Neos Logo

    Neos Therapeutics LP
    Denver, CO 80237

    LB8788
    Rev. 00
    05/2024

  • ​17 PRINCIPAL DISPLAY PANEL - 480 mL Bottle Label

    ​PRINCIPAL DISPLAY PANEL - 480 mL Bottle Label

    NDC: 62542-101-05

    Carbinoxamine Maleate Extended-Release Oral Suspension

    4 mg/5ml

    Shake Well Before Use

    Dose every 12 hours

    Dispense with an accurate millimeter measuring device

    Strawberry Banana Flavored

    Rx only 16 fl oz. (480 mL)

    Carbinoxamine Maleate Label

  • INGREDIENTS AND APPEARANCE
    CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION 
    carbinoxamine maleate suspension, extended release
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 62542-101
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CARBINOXAMINE MALEATE (UNII: 02O55696WH) (CARBINOXAMINE - UNII:982A7M02H5) CARBINOXAMINE MALEATE4 mg  in 5 mL
    Inactive Ingredients
    Ingredient NameStrength
    XANTHAN GUM (UNII: TTV12P4NEE)  
    POLYSORBATE 80 (UNII: 6OZP39ZG8H)  
    GLYCERIN (UNII: PDC6A3C0OX)  
    HIGH FRUCTOSE CORN SYRUP (UNII: XY6UN3QB6S)  
    TRIACETIN (UNII: XHX3C3X673)  
    SODIUM METABISULFITE (UNII: 4VON5FNS3C)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    SODIUM POLYSTYRENE SULFONATE (UNII: 1699G8679Z)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    WATER (UNII: 059QF0KO0R)  
    SUCROSE (UNII: C151H8M554)  
    POVIDONE (UNII: FZ989GH94E)  
    ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)  
    Product Characteristics
    Color    Score    
    ShapeSize
    FlavorSTRAWBERRY (Strawberry Banana) Imprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 62542-101-05480 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product06/01/2024
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDA authorized genericNDA02255606/01/2024
    Labeler - Neos Therapeutics LP (836126052)
    Establishment
    NameAddressID/FEIBusiness Operations
    Tris Pharma, Inc947472119manufacture(62542-101)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.